FDA-cleared profile

Medihub Prostate

JLK Inc.

MEDIHUB PROSTATE is an image processing software package that performs outlining, processing, viewing, and editing of prostate MR images. The software can support study review and analysis of prostate MR data with computed modules. The analysis result can be presented in various formats, including images overlaid onto source MR images and a structured report. MEDIHUB PROSTATE semi-automatically outlines the prostate based on MR images by contour, and it requires the user to edit with image manipulating tools and confirm the final result. The package provides additional functionalities including registered multiparametric-MRI viewing and combining MR sequences into a single image to support visualization. Edited PI-RADS report and semi annotated prostate region can be viewed in each single image in the final report. MEDIHUB PROSTATE is intended to be used by trained radiologists and urologists. Patient management decisions should not be made solely based on the analysis performed by MEDIHUB PROSTATE. Limitations: * MEDIHUB PROSTATE has been validated for use with Siemens 3T Vida and Skyra MRI machines. * MEDIHUB PROSTATE is also designed for use with the Siemens 3T T2 MRI series, supporting slice thicknesses ranging from 3.5 mm to 5 mm. * MEDIHUB PROSTATE has been tested on patients aged 55 years and above.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
MEDIHUB PROSTATE is an image processing software package that performs outlining, processing, viewing, and editing of prostate MR images. The software can support study review and analysis of prostate MR data with computed modules. The analysis result can be presented in various formats, including images overlaid onto source MR images and a structured report. MEDIHUB PROSTATE semi-automatically outlines the prostate based on MR images by contour, and it requires the user to edit with image manipulating tools and confirm the final result. The package provides additional functionalities including registered multiparametric-MRI viewing and combining MR sequences into a single image to support visualization. Edited PI-RADS report and semi annotated prostate region can be viewed in each single image in the final report. MEDIHUB PROSTATE is intended to be used by trained radiologists and urologists. Patient management decisions should not be made solely based on the analysis performed by MEDIHUB PROSTATE. Limitations: * MEDIHUB PROSTATE has been validated for use with Siemens 3T Vida and Skyra MRI machines. * MEDIHUB PROSTATE is also designed for use with the Siemens 3T T2 MRI series, supporting slice thicknesses ranging from 3.5 mm to 5 mm. * MEDIHUB PROSTATE has been tested on patients aged 55 years and above.
Public source Exact FDA submission Checked 2026-09-01

Exact-submission indication text from the ACR AI Central model card. FDA labeling remains controlling.

Intended users
Trained radiologists and urologists
Public source Exact FDA submission Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Care setting and population
Adult
Public source Exact FDA submission Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Workflow role
Segmentation or contouring
Public source Exact FDA submission Checked 2026-09-01

Conservative normalization of explicit wording in an exact-submission source.

Required input
MR images or data. Inclusion criteria: DICOM compatible multiparametric prostate MRI data including T2-weighted, DWI, ADC, and DCE sequences; patients aged 55 years and above; Siemens 3T Vida and Skyra MRI machines; slice thicknesses ranging from 3.5 mm to 5 mm
Public source Exact FDA submission Checked 2026-09-01

Conservative normalization of explicit wording in an exact-submission source.

Output and human action
The device outputs semi-automatic prostate region segmentation (contour/outline), total prostate gland volume, PSA density (using serum PSA input), regions of interest (ROIs) within the prostate with associated volume, average ADC value, PI-RADS score, and location. Results are presented as images overlaid onto source MR images and a structured report. DWI and DCE graphs are also provided. All measurements except prostate volume are performed manually by the user.
Public source Exact FDA submission Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Limitations
Research pending
Needs research Exact FDA submission Checked 2026-08-31

Confirm contraindications, unsupported populations, scanners, protocols, and known failure modes.

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233196
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
Public source Exact FDA submission Checked 2026-09-01

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
Prostate
Public source Exact FDA submission Checked 2026-09-01

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-06-21
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Public source Exact FDA submission Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Deployment and data flow
On-premise
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
Study type: Both. Cases: 114. Reference standard: Interpretation by Reviewing Clinician. Reader-study cases: 73. Readers: 3
Public source Exact FDA submission Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Medihub Prostate regulatory performance study summary

Stand-alone performance and reader study (ACR AI Central category) · Adult

exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K233196 · n=114 · Independence not established

K233196

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.

Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-08-31

Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
17Fields reviewed
6Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-02.

Alternatives

Related tools to compare

FDA-cleared K253682

DeepHealth ProstateAI

Quantib B.V.

FDA product code QDQ identifies this device class as Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer. A radiological computer...

Modality
MRI
Anatomy
Prostate
Decision
2026-04-29
FDA-cleared K242683

QP-Prostate® CAD

Quibim S.L.

FDA product code QDQ identifies this device class as Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer. A radiological computer...

Modality
MRI
Anatomy
Prostate
Decision
2025-03-18
FDA-cleared K241770

Prostate MR AI (VA10A)

Siemens Healthcare GmbH

Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior...

Modality
MRI
Anatomy
Prostate
Decision
2025-03-05
FDA-cleared K230772

Quantib Prostate

Quantib BV

FDA product code LLZ identifies this device class as System, Image Processing, Radiological. Consult the linked FDA record for the exact authorized indications for use.

Modality
MRI
Anatomy
Prostate
Decision
2023-04-17